Skip to main content
PMC home page
Oncology Letters logoLink to Oncology Letters
. 2020 Dec 23;21(2):147. doi: 10.3892/ol.2020.12408

MicroRNA-206 inhibits the proliferation, migration and invasion of colorectal cancer cells by regulating the c-Met/AKT/GSK-3β pathway

Jiayu Lyu 1, Yao Sun 2, Xizhi Li 3,✉, Huili Ma 4,✉
PMCID: PMC7877959  PMID: 33633805

Abstract

An imbalance in microRNA (miRNA/miR) expression is closely associated with tumorigenesis and progression. miR-206 is downregulated in different types of tumors, including colorectal cancer (CRC). However, the effects of miR-206 on the progression of CRC, and its underlying molecular mechanisms are yet to be elucidated. The present study aimed to investigate the effects of miR-206 on the proliferation, migration and invasion of colorectal cancer cells, and determine its potential molecular mechanism. The results of the present study demonstrated that the expression levels of miR-206 and c-Met were affected in HCT116 and SW480 cells by transfected with miR-206 mimic, inhibitor or small interfering RNA-c-Met. A Dual-luciferase reporter assay was performed to identify the miRNA targets. Cell proliferation, migration and invasion assays were also performed. The results demonstrated that overexpression of miR-206 significantly decreased the viability of HCT116 and SW480 cells. The results of the Transwell assay indicated that the cell migratory and invasive abilities were inhibited following transfection with miR-206 mimic. As a target of miR-206, knockdown of c-Met significantly suppressed cell viability, migration and invasion. In addition, c-Met knockdown or overexpression of miR-206 inhibited activation of the AKT/GSK-3β pathway. Collectively, these results suggest that miR-206 suppresses the proliferation, migration and invasion of CRC cells by targeting the c-Met/AKT/GSK-3β pathway.

Keywords: microRNA-206, c-Met, colorectal cancer, proliferation, migration, invasion

Introduction

Colorectal cancer (CRC) is the third most common malignancy among both sexes and the third leading cause of cancer-associated mortality worldwide, and the rates of incidence and mortality are 6.1 and 9.2% of the total cases in 2018 (1). Several factors, such as dysregulation of oncogenes or tumor suppressor genes, are involved in the occurrence and development of CRC, which affects the therapeutic efficacy and prognosis of CRC (2). In addition, tumor recurrence, invasion and metastasis are the main causes of mortality of patients with CRC (3). However, the underlying molecular mechanisms remain unknown.

MicroRNAs (miRNAs/miRs) belong to a family of endogenous non-coding small RNAs that usually consist of 19–24 nucleotides (4). miRNAs perform multiple functions by targeting the 3′-untranslated region (UTR) of target genes to induce transcriptional suppression or mRNA degradation (5–7). Previous studies have reported that abnormal expression of miRNAs exists in cancer tissues or cancer cell lines, which is associated with the initiation and progression of tumors, including breast cancer, bladder cancer and lung cancer (8–10). miRNAs also serve important roles in regulating tumor cell proliferation, apoptosis, migration and invasion by acting as oncogenes or tumor suppressors, or by targeting oncogenes or tumor suppressor genes (10,11).

miR-206 belongs to the miR-206/133b cluster, which is responsible for the growth and development of skeletal muscle (12). Recently, miR-206 expression has been demonstrated to be downregulated in different types of human tumors, including CRC (13,14), prostate (15,16), lung (17) and breast cancer (17,18), suggesting that miR-206 expression may be closely associated with the development of tumors. It has been reported that overexpression of miR-206 can decrease tumor cell viability, proliferation, migration, invasion and epithelial-to-mesenchymal transition, thus inhibiting the metastatic potential in breast cancer (8,19), while miR-206 knockdown promotes CRC promotion by activating C-C motif chemokine ligand 2 (CCL2) (20) and upregulating C-X-C chemokine receptor type 4 and VEFG-A (14). However, the underlying molecular mechanism of how miR-206 regulates the progression of CRC requires further investigation.

Thus, the present study aimed to investigate whether miR-206 inhibits CRC progression by regulating the c-Met/AKT/GSK-3 pathway. The effects of miR-206 on proliferation, migration, and invasion of CRC cells were assessed via gain or loss of function of miR-206. Taken together, the results of the present study demonstrated that overexpression of miR-206 suppressed the proliferation, migration and invasion of CRC cells by targeting the c-Met/AKT/GSK-3β pathway.

Materials and methods

Cell culture and treatment

The human colonic cancer cell lines, HCT116 and SW480, were purchased from The Cell Bank of Type Culture Collection of Chinese Academy of Sciences. Cells were maintained in DMEM (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (FBS; Cytiva), at 37°C in 5% CO2.

Reagents and transfection

miR-206 mimic, mimic negative control (mimic NC), miR-206 inhibitor, inhibitor NC, c-Met small interfering (si)RNA targeting c-Met (si-c-Met) and si-NC (scramble siRNA) were purchased from Guangzhou RiboBio Co., Ltd. The sequences of miR-206 mimic and inhibitor were as follows: miR-206 mimic, 5′-UGGAAUGUAAGGAAGUGUGUGG-3′; mimic NC, 5′-UUGUACUACACAAAAGUACUG-3′; miR-206 inhibitor, 5′-CCACACACUUCCUUACAUUCCA-3′; and inhibitor NC, 5′-CAGUACUUUUGUGUAGUACAA-3′. The sequences of si-c-Met and si-NC were as follows: si-c-Met sense, 5′-GGUGUUGUCUCAAUAUCAATT-3′, and antisense, 5′-UUGAUAUUGAGACAACACCTT-3′; si-NC sense, 5′-UUCUCCGAACGUGUCACGUTT-3′ and antisense, 5′-ACGUGACACGUUCGGAGAATT-3′. CRC cells were transfected with oligonucleotides using Lipofectamine® 2000 reagent (Thermo Fisher Scientific, Inc.), according to the manufacturer's instructions. Briefly, CRC cells were seeded into 6-well plates at a density of 1×105 cells/ml and transfected with 50 nM oligonucleotides or scrambled duplexes using transfection reagent at 37°C in a humidified incubator with 5% CO2 for 48 h. Transfection efficiency was assessed via reverse transcription-quantitative PCR or western blot analyses 48 h post-transfection.

RT-qPCR

Total RNA was extracted from CRC cells in each group using TRIzol reagent (Thermo Fisher Scientific, Inc.) and cDNA was synthesized using the One-Step miRNA RT kit (cat. no. 639503, Takara Bio, Inc.), at 37°C for 60 min. miR-206 expression was detected and analysed using qPCR using SYBR PremixEx Taq (cat. no. RR820A, Takara Bio, Inc.). U6 was used as the internal control to normalize relative miR-206 expression. The following primer sequences were used for qPCR: miR-206 RT primer, 5′-CTCAGCGGCTGTCGTGGACTGCGCGCTGCCGCTGAGCCACACAC-3′; miR-206 forward, 5′-GGCGGTGGAATGTAAGGAAG-3′ and reverse, 5′-GGCTGTCGTGGACTGCG-3′; U6 RT primer, 5′-GTCGTATCCAGTGCAGGGTCCGAGGTGCACTGGATACGACAAAATATGG-3′; and U6 forward, 5′-CTCGCTTCGGCAGCACA-3′ and reverse, 5′-CTCGCTTCGGCAGCACA-3′. The thermocycling conditions were as follows: 95°C for 10 min, followed by 40 cycles of amplification (95°C for 30 sec, 58°C for 60 sec, 72°C for 90 sec), and a final extension step of 72°C for 5 min. miRNA levels were quantified using the 2−ΔΔCq method (21).

Dual-luciferase reporter assay

The 3′-UTR of the human c-Met gene has a putative hsa-miR-206 binding sequence using the TargteScan database (release 7.2; http://www.targetscan.org/vert_72/). The luciferase reporter vector Pgl4Luc-RLuc (Addgene, Inc.) was used to establish a wild-type (WT) c-Met luciferase reporter plasmid or a mutant (MUT) c-Met luciferase reporter plasmid (Shanghai GenePharma Co., Ltd.). SW480 cells were subsequently co-transfected with miR-206 mimic (100 nM) or mimic NC and 200 ng WT or MUT c-Met 3′-UTR luciferase reporter plasmid using Lipofectamine® 2000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.). Following incubation for 48 h at 37°C, relative luciferase activities were detected using a Dual-luciferase reporter assay system (Beijing Abace Biotech, Co., Ltd.). and normalized by using the ratio of firefly to Renilla luciferase activity.

MTT assay

HCT116 or SW480 cells were transfected with oligonucleotides (miR-206 mimic, mimic NC, si-c-MET or si-NC), with concentrations ranging from 50–100 nM. Following incubation for 48 h at 37°C, cell viability was assessed via the MTT assay. Briefly, cells were seeded into 96-well microdilution plates at a density of 2×103 cells/well with DMEM containing 10% FBS. MTT reagent (cat. no. C0009S; Beyotime Biotech, Co., Ltd.) was added on 3 consecutive days at a final concentration of 5 mg/ml. Following the MTT incubation at 37°C for 4 h, the purple formazan crystals were dissolved using 150 µl DMSO and viability was subsequently analyzed at a wavelength of 570 nm, using an Enzyme Immunoassay Analyzer (Bio-Rad Laboratories, Inc.). Cell viability was calculated and normalized to the respective NC group.

Cell migration and invasion assays

Cell migration and invasion were assessed via the Transwell assays, with or without Matrigel. For the invasion assay, Transwell membranes were precoated with 50 µl diluted Matrigel (BD Biosciences) for 2 h at 37°C. Following transfection, 6×104 cells were plated in the upper chambers of Transwell plates in 200 µl serum-free DMEM medium, while 600 µl cell-free DMEM medium supplemented with 10% FBS was plated in the lower chambers. Following incubation for 24 h at 37°C, cells in the upper chambers were removed using a cotton swab. The invasive cells in the lower chambers were fixed with 100% pre-cold methanol for 10 min and stained with 0.1% crystal violet for 30 min at room temperature. For the migration assay, the same process was performed; however, Matrigel was not added in the upper chambers. Stained cells were counted in five randomly selected fields using a light microscope (Olympus Corporation; magnification, ×200).

Western blotting

Transfected cells were collected and lysed using RIPA lysis buffer (Beyotime Institute of Biotech). Extracted total protein was quantified using the BCA protein assay kit (cat. no. P0012; Beyotime Institute of Biotech). A total of 25 µg protein was separated via 8 or 10% SDS-PAGE and transferred onto PVDF membranes. The membranes were blocked with 5% skim milk for 1 h at room temperature and then incubated with primary antibodies against: AKT (1:1,000; cat. no. 9272; Cell Signaling Technology, Inc.), phosphorylated (p)-AKT (Ser473) (1:500; cat. no. 4060; Cell Signaling Technology, Inc.), GSK-3β (1:1,000; cat. no. 12456; Cell Signaling Technology, Inc.), phosphorylated (p)-GSK-3β (Ser9) (1:500; cat. no. 5558; Cell Signaling Technology, Inc.), β-actin (1:1,000; cat. no. 4970; Cell Signaling Technology, Inc.) and c-Met (1:1,000; cat. no. ab216330; Abcam) overnight at 4°C. Following the primary incubation, membranes were incubated with HRP-linked secondary antibodies (anti-mouse IgG, 1:10,000; cat. no. 7076; anti-rabbit IgG, 1:10,000, cat. no. 7074; Cell Signaling Technology, Inc.) for 1 h at room temperature. Immunoreactive bands were detected using Immobilon Forte Western HRP substrate reagents (EMD Millipore) and imaged using automatic chemiluminescence analyzer (Tanon Science and Technology Co., Ltd.). The gray value of target bands in each group was analyzed using ImageJ software (1.50d; National Institutes of Health).

Statistical analysis

Statistical analysis was performed using SPSS 22.0 software (IBM Corp.). All experiments were performed in triplicate and data are presented as the mean ± standard deviation. Paired or unpaired Student's t-test were used to compare differences between two groups, while one-way ANOVA followed by Tukey's post hoc test were used to compare differences between multiple groups. Spearman's correlation analysis was performed to assess the correlation between miR-206 and c-Met. P<0.05 was considered to indicate a statistically significant difference.

Results

miR-206 inhibits the proliferation, migration and invasion of CRC cells

As presented in Fig. 1A, miR-206 expression significantly increased in HCT116 and SW480 cells following transfection with miR-206 mimic (P<0.001), while transfection with miR-206 inhibitor significantly decreased miR-206 expression (P<0.001). In addition, overexpression of miR-206 significantly suppressed the proliferative, migratory and invasive abilities of CRC cells (P<0.05); however, transfection with miR-206 inhibitor promoted the proliferation, migration and invasion of cells (Fig. 1B-D).

Figure 1.

Figure 1.

Open in a new tab

Effects of miR-206 on the proliferation, migration and invasion of colorectal cancer cells. (A) Reverse transcription-quantitative PCR analysis was performed to detect miR-206 expression in HCT116 and SW480 cells following transfection with miR-206 mimic or inhibitor for 48 h. (B) Viability of HCT116 and SW480 cells was assessed via the MTT assay following transfection with miR-206 mimic or miR-206 inhibitor. (C and D) Cell migratory and invasive abilities were assessed via Transwell assays. *P<0.05, **P<0.01, ***P<0.001. miR, microRNA; NC, negative control.

c-Met is a direct target gene of miR-206

The potential target genes of miR-206 were screened using the TargetScan Human database. c-Met was identified as one of the potential targets of miR-206. To further verify that c-Met was a direct target gene of miR-206, the fluorescent reporter vectors with WT or MUT 3′-UTR sequences of c-Met were co-transfected with miR-206 mimic (Fig. 2A). As presented in Fig. 2B, relative luciferase activity of the c-Met WT 3′-UTR vector significantly decreased (P<0.01), whereas relative luciferase activity of the c-Met MUT 3′-UTR vector was not affected following transfection with miR-206 mimic, suggesting that c-Met is direct target gene of miR-206. Furthermore, Spearman's correlation analysis demonstrated that c-Met expression was negatively correlated with miR-206 expression (Fig. 2C).

Figure 2.

Figure 2.

Open in a new tab

c-Met is a direct target of miR-206. (A) Complementary sequences of miR-206 binding site in WT c-Met 3′-UTR and MUT c-Met 3′-UTR. (B) Luciferase activity was measured to assess the binding ability of miR-206 on the c-Met 3′-UTR WT or MUT in SW480 cells. (C) Spearman's correlation analysis was performed to determine the correlation between miR-206 and c-Met expression levels in SW480 cells. (D) mRNA and (E) protein expression levels of c-Met in HCT116 and SW480 cells were detected via reverse transcription-quantitative PCR and western blot analyses, respectively. *P<0.05, **P<0.01, ***P<0.001. miR, microRNA; WT, wild-type; UTR, untranslated region; MUT, mutant; NC, negative control.

The present study investigated whether c-Met was involved in the miR-206-mediated effects in CRC. As expected, overexpression of miR-206 significantly decreased the mRNA and protein expression levels of c-Met in HCT116 and SW480 cells (P<0.05 or P<0.01), the effects of which were reversed following transfection with miR-206 inhibitor (Fig. 2D and E).

Knockdown of c-Met inhibits the proliferation, migration and invasion of HCT116 and SW480 cells

As presented in Fig. 3A, c-Met protein expression significantly decreased in HCT116 and SW480 cells following transfection with si-c-Met. Knockdown of c-Met significantly decreased the viability, migration and invasion of CRC cells compared with the si-NC group (P<0.05; Fig. 3B-D).

Figure 3.

Figure 3.

Open in a new tab

Effects of c-Met on the proliferation, migration and invasion of colorectal cancer cells. (A) Western blot analysis was performed to detect c-Met protein expression in HCT116 and SW480 cells following transfection with si-c-Met. (B) Cell viability was assessed via the MTT assay following transfection for 24, 48 and 72 h. (C and D) Cell migratory and invasive abilities were assessed via Transwell assays. *P<0.05, **P<0.01, ***P<0.001. si, small interfering; NC, negative control.

miR-206-mediates the downregulation of c-Met and inhibits AKT/GSK-3β signaling

The expression levels of p-AKT (Ser473) and p-GSK-3β (Ser9) markedly decreased following inhibition of c-Met (Fig. 4A), suggesting that c-Met regulates the activation of AKT/GSK-3β signaling. In addition, overexpression of miR-206 was associated with decreased expression levels of p-AKT and p-GSK-3β, the effects of which were reversed following transfection with miR-206 inhibitor (Fig. 4B). Taken together, these results suggest that miR-206 mediates downregulation of c-Met and inhibits AKT/GSK-3β signaling.

Figure 4.

Figure 4.

Open in a new tab

Effects of c-Met and miR-206 on the AKT/GSK-3β signaling pathway. (A) Western blot analysis was performed to detect protein expression levels of p-AKT and p-GSK-3β in HCT116 and SW480 cells transfected with si-c-Met. (B) Western blot analysis was performed to detect protein expression levels of p-AKT and p-GSK-3β in HCT116 and SW480 cells transfected with miR-206 mimic or inhibitor. miR, microRNA; p-, phosphorylated; si, small interfering; NC, negative control.

Discussion

The initiation of malignant tumors usually begins from dysregulation of the normal growth regulatory mechanism, as well as cells undergoing hyperproliferation, evading apoptosis, becoming invasive and ultimately acquiring a malignant phenotype (22). Aberrant expression of miRNAs is closely associated with the tumorigenesis and progression of tumor, including CRC. For example, it has been reported that miRNAs can act as proto-oncogenes, such as miR-346, or tumor suppressors, such as miR-187-3p, to regulate cell proliferation, apoptosis and differentiation (23). Previous studies have demonstrated that miR-206 is dysregulated in different types of human cancer, including colon (24), lung (10), prostate (15) and breast cancer (19), suggesting that miR-206 serves an important role in tumorigenesis. In addition, clinical research has reported that serum miR-206 expression significantly decreases in patients with CRC compared with healthy controls, and was confirmed to be an independent prognostic indicator for CRC, as patients with CRC with low miR-206 expression experience poor overall survival and disease-free survival than those with high miR-206 expression, suggesting that miR-206 may be a promising biomarker for the diagnosis and prognosis of CRC (25). However, the underlying molecular mechanism of miR-206 in regulating the progression of CRC remains unknown, although several researchers have suggested the repression of miR-206 on proliferation, migration, invasion (21) and angiogenesis (14).

Previous studies have reported that overexpression of miR-206 can inhibit CRC cell migration and invasion (26), as well as prostaglandin E2-induced CRC cell proliferation, migration and invasion by targeting transmembrane 4 L six family member 1 (27). In addition, miR-206 knockdown promotes drug resistance and decreases the apoptosis of HCT116/FR cells (28). The results of the present study demonstrated that overexpression of miR-206 suppressed the proliferation, migration and invasion of HCT116 and SW480 cells, the effects of which were reversed following miR-206 knockdown, suggesting that miR-206 may be involved in the development of CRC by suppressing the proliferation, migration and invasion of CRC cells.

c-Met, also known as MET, acts as an oncogene and has been identified as a direct target of miR-206 (29), and has also been demonstrated to regulate proliferation, invasion and metastasis of tumor cells (10,30). It has been reported that miR-206 suppresses the proliferation, migration and invasion of lung cancer cells by downregulating c-Met signaling (31,32). c-Met upregulation has been observed in different types of human cancer, including CRC and exhibits oncogenic activity (33,34). It has been demonstrated that specific inhibition of the STAT3/c-Met pathway can potentially neutralize the intrahepatic metastatic implantation and increase growth over a short-lived temporal window caused by radiofrequency ablation of healthy liver in an intrahepatic CRC mice model (35). A positive association between c-Met expression and tumor stages of CRC liver metastasis and lymph node metastasis has been suggested (36), indicating that c-Met expression may be a significant prognostic factor in CRC metastasis. In addition, a previous study revealed that overexpression of miR-206 and inhibition of the c-Met/ERK/Elk-1/HIF-1α/VEGF-A pathway by CCL19 suppresses angiogenesis in CRC (37).

The results of the present study demonstrated that miR-206 expression was negatively correlated with c-Met expression in CRC cells, and identified that c-Met knockdown significantly inhibited the proliferation, migration and invasion of CRC cells. Taken together, these results suggest that miR-206 may regulate the progression of CRC cells by targeting c-Met. It has been reported that c-Met can mediate the activation of several intracellular signaling pathways, including the AKT/GSK-3β, STAT3, SRC/FAK and MAPK/ERK pathways (38–40). Activation of these pathways results in the emergence of diverse cellular hallmarks of cancer, including cell proliferation, survival, inhibition of inflammation and apoptosis, migration, invasion and metastasis (41–43).

The present study investigated the expression levels of p-Akt and p-GSK-3β and demonstrated that c-Met knockdown significantly decreased the expression levels of these factors. Further investigation revealed that overexpression of miR-206 decreased the expression levels of p-Akt and p-GSK-3β, the effects of which were reversed following miR-206 knockdown. Collectively, these results suggest that miR-206 may downregulate activity of the Akt/GSK-3β pathway by targeting c-Met, thus suppressing the proliferation, migration and invasion of CRC cells. Further research is required to confirm whether the effect of miR-206 on CRC cells can be reversed by specifically activating the Akt/GSK-3β pathway, thus providing further evidence to clarify the molecular mechanism of miR-206 in regulating the progression of CRC cells. In addition, whether miR-206 can regulate tumor growth and metastasis via the Akt/GSK-3β pathway requires further investigation.

In conclusion, the results of the present study demonstrated that miR-206 suppressed the proliferation, migration and invasion of CRC cells by targeting the c-Met/AKT/GSK-3β signaling pathway. These findings demonstrate the antitumor effects of miR-206 and its underlying molecular mechanism, which may aid in the development of more effective and promising therapies against CRC.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author upon reasonable request.

Authors' contributions

JL performed the experiments and drafted the initial manuscript. YS performed the statistical analysis. HM and XL conceived and designed the experiments. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

  • 1.Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi: 10.3322/caac.21492. [DOI] [PubMed] [Google Scholar]
  • 2.Zeng M, Zhu L, Li L, Kang C. miR-378 suppresses the proliferation, migration and invasion of colon cancer cells by inhibiting SDAD1. Cell Mol Biol Lett. 2017;22:12. doi: 10.1186/s11658-017-0041-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Wang B, Liu G, Ding L, Zhao J, Lu Y. FOXA2 promotes the proliferation, migration and invasion, and epithelial mesenchymal transition in colon cancer. Exp Ther Med. 2018;16:133–140. doi: 10.3892/etm.2018.6157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Rupaimoole R, Calin GA, Lopez-Berestein G, Sood AK. miRNA deregulation in cancer cells and the tumor microenvironment. Cancer Discov. 2016;6:235–246. doi: 10.1158/2159-8290.CD-15-0893. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Ma W, Liu B, Li J, Jiang J, Zhou R, Huang L, Li X, He X, Zhou Q. MicroRNA-302c represses epithelial-mesenchymal transition and metastasis by targeting transcription factor AP-4 in colorectal cancer. Biomed Pharmacother. 2018;105:670–676. doi: 10.1016/j.biopha.2018.06.025. [DOI] [PubMed] [Google Scholar]
  • 6.Dou C, Liu Z, Xu M, Jia Y, Wang Y, Li Q, Yang W, Zheng X, Tu K, Liu Q. miR-187-3p inhibits the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting S100A4. Cancer Lett. 2016;381:380–390. doi: 10.1016/j.canlet.2016.08.011. [DOI] [PubMed] [Google Scholar]
  • 7.Tu K, Liu Z, Yao B, Han S, Yang W. MicroRNA-519a promotes tumor growth by targeting PTEN/PI3K/AKT signaling in hepatocellular carcinoma. Int J Oncol. 2016;48:965–974. doi: 10.3892/ijo.2015.3309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Yin K, Yin W, Wang Y, Zhou L, Liu Y, Yang G, Wang J, Lu J. MiR-206 suppresses epithelial mesenchymal transition by targeting TGF-β signaling in estrogen receptor positive breast cancer cells. Oncotarget. 2016;7:24537–24548. doi: 10.18632/oncotarget.8233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Xu X, Zhu Y, Liang Z, Li S, Xu X, Wang X, Wu J, Hu Z, Meng S, Liu B, et al. c-Met and CREB1 are involved in miR-433-mediated inhibition of the epithelial-mesenchymal transition in bladder cancer by regulating Akt/GSK-3beta/Snail signaling. Cell Death Dis. 2016;7:e2088. doi: 10.1038/cddis.2015.274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Chen QY, Jiao DM, Yan L, Wu YQ, Hu HZ, Song J, Yan J, Wu LJ, Xu LQ, Shi JG. Comprehensive gene and microRNA expression profiling reveals miR-206 inhibits MET in lung cancer metastasis. Mol Biosyst. 2015;11:2290–2302. doi: 10.1039/C4MB00734D. [DOI] [PubMed] [Google Scholar]
  • 11.Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 2007;(96 Suppl):R40–R44. [PubMed] [Google Scholar]
  • 12.Ma G, Wang Y, Li Y, Cui L, Zhao Y, Zhao B, Li K. MiR-206, a key modulator of skeletal muscle development and disease. Int J Biol Sci. 2015;11:345–352. doi: 10.7150/ijbs.10921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Zhu H, He G, Wang Y, Hu Y, Zhang Z, Qian X, Wang Y. Long intergenic noncoding RNA 00707 promotes colorectal cancer cell proliferation and metastasis by sponging miR-206. Onco Targets Ther. 2019;12:4331–4340. doi: 10.2147/OTT.S198140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Zheng X, Ma YF, Zhang XR, Li Y, Zhao HH, Han SG. Circ_0056618 promoted cell proliferation, migration and angiogenesis through sponging with miR-206 and upregulating CXCR4 and VEGF-A in colorectal cancer. Eur Rev Med Pharmacol Sci. 2020;24:4190–4202. doi: 10.26355/eurrev_202004_20999. [DOI] [PubMed] [Google Scholar]
  • 15.Wang Y, Xu H, Si L, Li Q, Zhu X, Yu T, Gang X. MiR-206 inhibits proliferation and migration of prostate cancer cells by targeting CXCL11. Prostate. 2018;78:479–490. doi: 10.1002/pros.23468. [DOI] [PubMed] [Google Scholar]
  • 16.Yang N, Wang L, Liu J, Liu L, Huang J, Chen X, Luo Z. MicroRNA-206 regulates the epithelial-mesenchymal transition and inhibits the invasion and metastasis of prostate cancer cells by targeting Annexin A2. Oncol Lett. 2018;15:8295–8302. doi: 10.3892/ol.2018.8395. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Liao M, Peng L. MiR-206 may suppress non-small lung cancer metastasis by targeting CORO1C. Cell Mol Biol Lett. 2020;25:22. doi: 10.1186/s11658-020-00216-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Fan C, Liu N, Zheng D, Du J, Wang K. MicroRNA-206 inhibits metastasis of triple-negative breast cancer by targeting transmembrane 4 L6 family member 1. Cancer Manag Res. 2019;11:6755–6764. doi: 10.2147/CMAR.S199027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Fu Y, Shao ZM, He QZ, Jiang BQ, Wu Y, Zhuang ZG. Hsa-miR-206 represses the proliferation and invasion of breast cancer cells by targeting Cx43. Eur Rev Med Pharmacol Sci. 2015;19:2091–2104. [PubMed] [Google Scholar]
  • 20.Shengnan J, Dafei X, Hua J, Sunfu F, Xiaowei W, Liang X. Long non-coding RNA HOTAIR as a competitive endogenous RNA to sponge miR-206 to promote colorectal cancer progression by activating CCL2. J Cancer. 2020;11:4431–4441. doi: 10.7150/jca.42308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402–408. doi: 10.1006/meth.2001.1262. [DOI] [PubMed] [Google Scholar]
  • 22.Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–866. doi: 10.1038/nrc1997. [DOI] [PubMed] [Google Scholar]
  • 23.Pan JY, Sun CC, Bi ZY, Chen ZL, Li SJ, Li QQ, Wang YX, Bi YY, Li DJ. miR-206/133b cluster: A weapon against lung cancer? Mol Ther Nucleic Acids. 2017;8:442–449. doi: 10.1016/j.omtn.2017.06.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Wang XW, Xi XQ, Wu J, Wan YY, Hui HX, Cao XF. MicroRNA-206 attenuates tumor proliferation and migration involving the downregulation of NOTCH3 in colorectal cancer. Oncol Rep. 2015;33:1402–1410. doi: 10.3892/or.2015.3731. [DOI] [PubMed] [Google Scholar]
  • 25.Liu X, Zheng W, Zhang X, Dong M, Sun G. The diagnostic and prognostic value of serum miR-206 in colorectal cancer. Int J Clin Exp Pathol. 2017;10:7528–7533. [PMC free article] [PubMed] [Google Scholar]
  • 26.Sun P, Sun D, Wang X, Liu T, Ma Z, Duan L. miR-206 is an independent prognostic factor and inhibits tumor invasion and migration in colorectal cancer. Cancer Biomark. 2015;15:391–396. doi: 10.3233/CBM-150489. [DOI] [PubMed] [Google Scholar]
  • 27.Park YR, Seo SY, Kim SL, Zhu SM, Chun S, Oh JM, Lee MR, Kim SH, Kim IH, Lee SO, et al. MiRNA-206 suppresses PGE2-induced colorectal cancer cell proliferation, migration, and invasion by targetting TM4SF1. Biosci Rep. 2018;38:BSR20180664. doi: 10.1042/BSR20180664. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Meng X, Fu R. miR-206 regulates 5-FU resistance by targeting Bcl-2 in colon cancer cells. Onco Targets Ther. 2018;11:1757–1765. doi: 10.2147/OTT.S159093. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Ren XL, He GY, Li XM, Men H, Yi LZ, Lu GF, Xin SN, Wu PX, Li YL, Liao WT, et al. MicroRNA-206 functions as a tumor suppressor in colorectal cancer by targeting FMNL2. J Cancer Res Clin Oncol. 2016;142:581–592. doi: 10.1007/s00432-015-2053-8. [DOI] [PubMed] [Google Scholar]
  • 30.Dai C, Xie Y, Zhuang X, Yuan Z. MiR-206 inhibits epithelial ovarian cancer cells growth and invasion via blocking c-Met/AKT/mTOR signaling pathway. Biomed Pharmacother. 2018;104:763–770. doi: 10.1016/j.biopha.2018.05.077. [DOI] [PubMed] [Google Scholar]
  • 31.Mataki H, Seki N, Chiyomaru T, Enokida H, Goto Y, Kumamoto T, Machida K, Mizuno K, Nakagawa M, Inoue H. Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR oncogenic signaling in lung squamous cell carcinoma. Int J Oncol. 2015;46:1039–1050. doi: 10.3892/ijo.2014.2802. [DOI] [PubMed] [Google Scholar]
  • 32.Chen X, Tong ZK, Zhou JY, Yao YK, Zhang SM, Zhou JY. MicroRNA-206 inhibits the viability and migration of human lung adenocarcinoma cells partly by targeting MET. Oncol Lett. 2016;12:1171–1177. doi: 10.3892/ol.2016.4735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Raghav K, Bailey AM, Loree JM, Kopetz S, Holla V, Yap TA, Wang F, Chen K, Salgia R, Hong D. Untying the gordion knot of targeting MET in cancer. Cancer Treat Rev. 2018;66:95–103. doi: 10.1016/j.ctrv.2018.04.008. [DOI] [PubMed] [Google Scholar]
  • 34.Zhao Y, Tao Q, Li S, Zheng P, Liu J, Liang X. Both endogenous and exogenous miR-139-5p inhibit Fusobacterium nucleatum-related colorectal cancer development. Eur J Pharmacol. 2020;888:173459. doi: 10.1016/j.ejphar.2020.173459. [DOI] [PubMed] [Google Scholar]
  • 35.Liao H, Ahmed M, Markezana A, Zeng G, Stechele M, Galun E, Goldberg SN. Thermal ablation induces transitory metastatic growth by means of the STAT3/c-Met molecular pathway in an intrahepatic colorectal cancer mouse model. Radiology. 2020;294:464–472. doi: 10.1148/radiol.2019191023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Yao JF, Li XJ, Yan LK, He S, Zheng JB, Wang XR, Zhou PH, Zhang L, Wei GB, Sun XJ. Role of HGF/c-Met in the treatment of colorectal cancer with liver metastasis. J Biochem Mol Toxicol. 2019;33:e22316. doi: 10.1002/jbt.22316. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Xu Z, Zhu C, Chen C, Zong Y, Feng H, Liu D, Feng W, Zhao J, Lu A. CCL19 suppresses angiogenesis through promoting miR-206 and inhibiting Met/ERK/Elk-1/HIF-1α/VEGF-A pathway in colorectal cancer. Cell Death Dis. 2018;9:974. doi: 10.1038/s41419-018-1010-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: Rationale and progress. Nat Rev Cancer. 2012;12:89–103. doi: 10.1038/nrc3205. [DOI] [PubMed] [Google Scholar]
  • 39.Viticchiè G, Muller PAJ. c-Met and other cell surface molecules: Interaction, activation and functional consequences. Biomedicines. 2015;3:46–70. doi: 10.3390/biomedicines3010046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Yamaoka T, Kusumoto S, Ando K, Ohba M, Ohmori T. Receptor tyrosine kinase-targeted cancer therapy. Int J Mol Sci. 2018;19:3491. doi: 10.3390/ijms19113491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Organ SL, Tsao MS. An overview of the c-MET signaling pathway. Ther Adv Med Oncol. 2011;3(Suppl 1):S7–S19. doi: 10.1177/1758834011422556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Comoglio PM, Trusolino L, Boccaccio C. Known and novel roles of the MET oncogene in cancer: A coherent approach to targeted therapy. Nat Rev Cancer. 2018;18:341–358. doi: 10.1038/s41568-018-0002-y. [DOI] [PubMed] [Google Scholar]
  • 43.Lu Z, Song N, Shen B, Xu X, Fang Y, Shi Y, Ning Y, Hu J, Dai Y, Ding X, et al. Syndecan-1 shedding inhibition to protect against ischemic acute kidney injury through HGF target signaling pathway. Transplantation. 2018;102:e331–e344. doi: 10.1097/TP.0000000000002170. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The datasets used and/or analyzed during the present study are available from the corresponding author upon reasonable request.

Articles from Oncology Letters are provided here courtesy of Spandidos Publications

RESOURCES